What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study

What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study

Abstract Background Neoadjuvant therapy with dual HER2 blockade improved pathological complete response (pCR) rate in HER2‐positive breast cancer patients. Nevertheless, it would be desirable to identify patients exquisitely responsive to single agent trastuzumab to minimize or avoid overtreatment....

Full description

Bibliographic Details
Main Authors: Sara Pizzamiglio, Giulia Cosentino, Chiara M. Ciniselli, Loris De Cecco, Alessandra Cataldo, Ilaria Plantamura, Tiziana Triulzi, Sarra El‐abed, Yingbo Wang, Mohammed Bajji, Paolo Nuciforo, Jens Huober, Susan L. Ellard, David L. Rimm, Andrea Gombos, Maria Grazia Daidone, Paolo Verderio, Elda Tagliabue, Serena Di Cosimo, Marilena V. Iorio
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Cancer Medicine
Subjects:
biomarkers
breast cancer
HER2
microRNA
trastuzumab
Online Access:https://doi.org/10.1002/cam4.4449

Internet

https://doi.org/10.1002/cam4.4449

Similar Items